Phi29 DNA-Packaging Motor for Nanomedicine

创新的生物机器，如纳米电机和膜通道，激励着 仿生设备，可以为疾病诊断和治疗提供精确的细胞过程控制 治疗。Phi29是迄今为止建造的最强大的生物推进器。马达是可切换的，强调了它的 与所有其他体外病毒包装马达相比，DNA插入效率最高，使马达成为 在纳米技术应用中作为机械部件的可行选择。中国的长期目标是 拟建的纳米药物输送中心将创建生物兼容的膜和阵列， 嵌入式phi29DMA-用于医药应用的封装电机。这将通过专注于 关于三个关键研究领域：对phi29马达进行逆向工程；将有源纳米马达整合到 脂质双层；以及开发能够实现药物输送和诊断的活性纳米马达阵列。 该中心的短期目标是创造嵌入phi29 DNA的脂质体和阵列结构- 包装马达，用于DNA和药物的被动和主动运输。该中心将开发混合动力车 结合了生物纳米发动机和合成输送系统的最佳特性的系统 已经达到临床验收。初步工作将提供该结构的工程规格 以及phi29纳米电机的工作机制，这将使我们能够生产出工程的、混合的、合成的 和功能性纳米马达。将活性phi29纳米摩尔引入脂质体将是一个主要的推动力 将使已经在临床上被接受的治疗方法能够进行纳米级的控制 但仍然只为癌症和感染性疾病等复杂疾病的治疗提供钝器 疾病。更多的团队工作将利用我们对重新设计的膜添加的理解 马达制造用于诊断应用的纳米机械原型设备，定向交付 治疗学和各种纳米机械在医学上的应用。这些应用程序和 物理作用、能量转导和跨膜运输的工程原理 膜适应马达的性能将由我们的跨学科团队进行说明，包括 物理学家、化学家、工程师、数学家、内科医生和分子生物学家。

Innovative biological machines, such as nanomotors and membrane channels, inspire the development of biomimetic devices that can provide the exquisite control of cellular processes for disease diagnostics and treatment. The phi29 is the strongest biomotor constructed to date. The motor is switchable, underscoring its highest efficiency in DNA insertion compared to all other in vitro viral packaging motors, making the motor a viable option as a mechanical component in nanotechnology applications. The long-term goal of the proposed Nanomotor Drug Delivery Center is to create biologically compatible membranes and arrays with embedded phi29 DMA-packaging motors for applications in medicine. This will be accomplished by focusing on three key areas of study: reverse engineering the phi29 motor; incorporating the active nanomotor into lipid bilayers; and developing active nanomotor arrays that enable drug delivery and diagnostics. The short-term goal of this center is to create liposomes and array structures with embedded phi29 DNA- packaging motors for both passive and active transport of DNA and drugs. The Center will develop hybrid systems that combine the best features of the biological nanomotor and synthetic delivery systems that have already achieved clinical acceptance. Initial efforts will provide engineering specifications for the structure and working mechanism of the phi29 nanomotorthat will enable us to produce engineered, hybrid, synthetic and functional nanomotors. Incorporation of active phi29 nanomotors in liposomes will be a major thrust that will enable nanoscale control for therapeutic approaches that have already gained acceptance in the clinic but still provide only blunt instruments for therapy of complex conditions such as cancer and infectious diseases. Additional team efforts will exploit our understanding of the reengineered membrane-addapted motor to create prototype nanomechanical devices for diagnostic applications, targeted delivery of therapeutics and for various nanomachines with application in medicine. These applications and the engineering principles underlying the physical action, energy transduction and transmembrane transport capabilities of the membrane adapted motors will be elucidated by our interdisciplinary team including physicists, chemists, engineers, mathematicians, physicians, and molecular biologists.